

Prior Authorization Form

CAREFIRST

Dry Eye Disease Agents PA with Limit

This fax machine is located in a secure location as required by HIPAA regulations.  
Complete/review information, sign and date. Fax signed forms to CVS/Caremark at **1-888-836-0730**.  
Please contact CVS/Caremark at **1-800-294-5979** with questions regarding the prior authorization process.  
When conditions are met, we will authorize the coverage of Dry Eye Disease Agents PA with Limit.

Drug Name  
(specify drug) \_\_\_\_\_

Quantity

Frequency

Strength

Route of Administration

Expected Length of Therapy

Patient Information

Patient Name: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Patient Group No.: \_\_\_\_\_

Patient DOB: \_\_\_\_\_

Patient Phone: \_\_\_\_\_

Prescribing Physician

Physician Name: \_\_\_\_\_

Physician Phone: \_\_\_\_\_

Physician Fax: \_\_\_\_\_

Physician Address: \_\_\_\_\_

City, State, Zip: \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code:** \_\_\_\_\_

Comments: \_\_\_\_\_

Please circle the appropriate answer for each question.

1. Is the requested drug being prescribed for dry eye disease?

Y N

[If Yes, then go to 2. If No, then no further questions.]

2. Is the request for Cequa, Miebo, Restasis, Tyrvaya, Vevye, or Xiidra?

Y N

[If Yes, then go to 4. If No, then go to 3.]

3. Is the request for Eysuvis for short-term use (up to 2 weeks)?

Y N

[If Yes, then go to 7. If No, then no further questions.]

4. Is this request for continuation of therapy?

Y N

[If Yes, then go to 5. If No, then go to 6.]	
5. Has the patient achieved or maintained improvement in their signs and symptoms of dry eye disease from baseline (e.g., ocular irritation, redness, mucous discharge, reduced visual function, ocular surface damage, reduced tear production)?	<input type="text" value="Y"/> <input type="text" value="N"/>
[If Yes, then go to 6. If No, then no further questions.]	
6. Does the patient require MORE than the plan allowance PER MONTH (unless specified otherwise) of any of the following: A) Cequa: 60 vials, B) Miebo: 1 multi-dose bottle (3 mL), C) Restasis: 60 vials OR 1 multi-dose bottle (5.5 mL) / 28 days, D) Tyrvaya: 2 nasal spray bottles (8.4 mL), E) Vevye: 1 multi-dose bottle (2 mL), F) Xiidra: 60 containers (1 carton)?	<input type="text" value="Y"/> <input type="text" value="N"/>
[No further questions.]	
7. Does the patient require more than the plan allowance of 2 bottles (16.6 mL) per 90 days of Eysuvis?	<input type="text" value="Y"/> <input type="text" value="N"/>
[No further questions.]	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

<b>Prescriber (Or Authorized) Signature and Date</b>
--